Screener
Dianthus Therapeutics DNTH Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss on currency exchange, net | (15) | (22) |
| Other expense | (249) | (98) |
| Total other income | 5,699 | 3,666 |
| Net loss | $(40,834) | $(29,511) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.85) | $(0.82) |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted | 48,032,742 | 35,790,700 |
| Comprehensive loss: | ||
| Net loss | $(40,834) | $(29,511) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's net income?
- Dianthus Therapeutics (DNTH) reported net income of -$40.83M in Q1 2026.
- How has Dianthus Therapeutics's net income changed year-over-year?
- Dianthus Therapeutics's net income decreased by 38.4% year-over-year, from -$29.51M to -$40.83M.
- What is the long-term trend for Dianthus Therapeutics's net income?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's net income has grown at a 6.1% compound annual growth rate (CAGR), from -$71.14M to -$84.97M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Dianthus Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude